News >

Salvage Daratumumab Reaches High ORR in Relapsed Myeloma Following Allogeneic SCT

Virginia Powers, PhD
Published: Tuesday, Apr 02, 2019

Sonja Essmann MD

Sonja Essmann MD

Patients with multiple myeloma who relapsed following allogeneic stem cell transplantation (SCT) and also failed several posttransplant therapies demonstrated a strong response to daratumumab (Darzalex) salvage therapy, according to findings presented at the 2019 European Society for Blood and Marrow Transplantation Annual Meeting.

Further research is needed to investigate the role of daratumumab in combination with immunomodulatory agents or proteasome inhibitors in the second-line setting, the authors concluded in their poster.
Essmann S, von Pein U-M, Klyuchnikov E, et al. Daratumumab as salvage therapy in relapsed/refractory multiple myeloma patients after allogenic stem cell transplantation. Presented at: 2019 European Society for Blood and Marrow Transplantation Annual Meeting; March 24 to 27, 2019; Frankfurt, Germany. Abstract B249.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication